Timing varies far more between individuals than one average number suggests. The years before the final period carry most of the symptoms and most of the measurable hormonal change, which is why a trend over time reads better than a single result.
Menopause is one specific day, the day on which 12 consecutive months have passed since the final menstrual period with no other explanation for the pause. That definition makes it a point identified in hindsight. Nobody can recognise the final period while it is happening, only a year after the fact, which is why the whole subject is discussed in ranges rather than dates.
Three words get used loosely. Perimenopause is the transition, the stretch of months or years when cycles and hormones become erratic. Menopause is the single point 12 months after the last bleed. Postmenopause is everything after that point, which is most of the rest of life.
The underlying biology is straightforward. The ovaries hold a finite pool of follicles, set before birth and declining steadily across life. In each cycle a group of follicles is recruited, one usually matures and releases an egg, and those growing follicles produce most of the body's estradiol along with other signalling hormones. Ovarian hormones feed back to the pituitary gland and keep its output in check. As the pool of responsive follicles thins, that feedback weakens, pituitary signalling rises in an attempt to push the ovaries harder, and cycles shorten, then become irregular, then stop. When the ovary no longer responds at all, periods end for good.
None of this is a disease. It is a scheduled change in an endocrine system. The practical questions are when it happens, what it feels like while it is happening, and what it means for the decades that follow.
The figure usually quoted for natural menopause is around 51, and most women reach it somewhere between 45 and 55. An average is a midpoint, not a forecast. Roughly half of women reach menopause before that figure and half after it, and a woman who stops at 47 and a woman who stops at 54 are both comfortably inside the ordinary range.
Reported averages differ a little between populations and between data sets, partly because the date is recalled rather than recorded, partly because smoking rates, surgical history and general health differ between groups. Those differences are modest. The headline picture is stable, a transition that usually begins somewhere in the forties and completes somewhere in the early fifties.
What varies far more than the end point is the length of the run-up. Some women notice a few months of irregular cycles and then stop. Others spend several years with changing bleeding patterns, disrupted sleep and hot flushes before the final period arrives. Two women who reach menopause at exactly the same age can have completely different experiences of the decade before it.
This is also why a population average is a weak planning tool for one person. It describes a group. It says nothing about how much ovarian reserve you personally have, how your cycle length is trending, or whether the changes you noticed at 43 are the beginning of the transition or something unrelated. For that, the useful inputs are your own cycle history, your family pattern, and hormone testing read as a trend rather than as a one-off snapshot.
Menopause before the age of 45 is described as early, and loss of ovarian function before 40 is described as premature ovarian insufficiency 1. The two labels overlap but are not interchangeable. Premature ovarian insufficiency describes ovarian function failing well ahead of schedule, sometimes with periods that stop and start again, and it is assessed with repeated testing over time rather than a single result 1.
| Term | Usual age definition | What it describes |
|---|---|---|
| Premature ovarian insufficiency | Before 40 | Ovarian function declining or failing far earlier than expected, confirmed with repeat assessment over time |
| Early menopause | 40 to 44 | A final period earlier than the typical window, with the same biology as natural menopause |
| Typical window for natural menopause | 45 to 55 | The range into which most women fall, averaging around 51 |
| Later menopause | After 55 | A final period later than the usual window |
| Induced menopause | Any age | Ovarian function ending because of surgery or other medical care rather than natural ageing 1 |
Research suggests that premature ovarian insufficiency and early menopause occur more often across the world than is generally assumed 2. That matters because an early transition is easy to misread as stress, overtraining or a thyroid problem, and because the long-term health picture after an early menopause differs from the picture after an average one.
A single out of range hormone result does not place anyone in one of these categories. Hormones in the transition move around, and the categories above are clinical definitions applied after a pattern has been established. An early or unexpected result is worth discussing with a clinician rather than self-interpreting.
The strongest routine signal is family history, followed by anything that removes or damages ovarian tissue. Research suggests that genetic factors explain a substantial share of the variation in age at menopause, which is why the timing reported by a mother or sister is often informative, without being a rule 3.
Smoking is the most consistently reported modifiable factor. Research suggests that smoking is associated with reaching natural menopause at an earlier age 3.
Surgery is the most abrupt cause. Removal of both ovaries ends ovarian hormone production immediately rather than gradually, which is categorised as induced menopause 1. Other medical care directed at the pelvis or at the body as a whole can also reduce or end ovarian function, and that possibility is usually discussed in advance by the clinician organising it 1. Removal of the uterus alone is different. Periods stop, but ovaries that are left in place keep producing hormones, so the hormonal transition still happens later, simply without a bleeding calendar to mark it.
Some medicines can alter cycles, hormone levels or both. Ask your prescriber whether anything you take is relevant before reading much into a single result.
Some autoimmune and chromosomal conditions are part of the picture too, and these are among the causes considered in people with ovarian insufficiency arising well before the expected age 1.
Diet sits at the softer end of the scale. A systematic review and meta-analysis found that certain dietary factors are associated with small differences in the age at natural menopause, with effect sizes that are modest next to genetics and surgery 4.
Put together, timing is mostly inherited, partly shaped by medical history, and only slightly nudged by daily habits. That is worth knowing because it reframes the question. The useful goal is not to delay menopause, it is to know roughly where you are in the process and to look after the things that respond well to attention, such as cardiometabolic health, muscle, bone and sleep.
Perimenopause is the transition leading up to menopause, and for most women it begins in the forties, occasionally in the late thirties, and runs for several years. It is defined by change rather than by absence. Cycles shorten or lengthen, bleeding gets heavier or lighter, and symptoms appear while periods are still happening. Menopause itself is the end point of that process, not the process.
The hormonal pattern during perimenopause is erratic rather than steadily declining. Estradiol can swing high before it falls, and pituitary signalling can be raised in one cycle and ordinary in the next. That instability is the reason a single blood test taken in perimenopause is so hard to interpret on its own, and the reason symptoms often arrive before any result looks unusual.
Research suggests that hot flushes and night sweats are among the most commonly reported symptoms of the transition, with prevalence varying widely between populations and with other common complaints including disturbed sleep, mood changes, joint aches and genitourinary symptoms 5. Symptom load does not track neatly with how close someone is to their final period, so feeling unaffected does not mean the transition has not started, and feeling flattened by symptoms does not mean it is nearly over.
If the timing of this stage is the question you actually came for, the dedicated guide to when does perimenopause start goes through the early signals in more detail.
FSH, or follicle-stimulating hormone, is a pituitary hormone that rises as the ovaries become less responsive, and it is measured with a standard blood draw, usually taken early in the cycle while cycles are still happening. The FSH guide covers the marker in full, including how a result is interpreted. Labs commonly regard roughly 1 to 15 mIU/mL as a typical reference range during the reproductive years, and FitScript's optimal range for FSH is 1.5 to 10 mIU/mL. Optimal ranges are FitScript's optimization targets rather than diagnostic cut-offs, and reference ranges vary by lab, by age and by the cycle day on which the sample is drawn.
No blood test gives a date, and the honest ceiling on current testing is a narrower window rather than a calendar entry. The marker that carries the most information about the remaining follicle pool is anti-Mullerian hormone, or AMH, produced by small developing follicles in the ovary.
Research suggests that AMH carries real information about the likely timing of menopause, with accuracy that improves as a woman gets closer to the event and that remains limited for pinpointing an individual's final period 6. Studies suggest that the markers available today narrow the plausible window rather than fix a date, which is why prediction is framed in years rather than months 3.
Pituitary markers behave differently. They are more useful for describing where ovarian function currently sits than for forecasting, and during perimenopause they can move substantially between cycles, so one raised value does not settle anything. A pattern across repeated samples, read alongside cycle history and symptoms, carries far more weight than any individual number. The specific question of what a particular level signals is covered in the guide to what fsh level indicates menopause.
There is also a practical limit worth stating plainly. Testing is most informative when there is a reason to test, such as periods changing well before the expected age, symptoms that are hard to place, or a family history of early menopause. Testing purely to predict a date tends to produce numbers that feel precise and are not. Interpretation of any result belongs with a clinician who can see the full context.
Read it in three steps, what the value shows, what it may reflect, and what is worth raising with a clinician. That sequence keeps a single number in proportion.
First, the observation. A hormone result describes one moment, on one cycle day, in one lab's assay. Reference ranges differ between labs, and for cycling women they also differ by phase, so the same blood would be reported differently in two different settings.
Second, what it may reflect. A raised pituitary gonadotrophin with a low estradiol in a woman in her late forties who has had irregular cycles for a year may reflect declining ovarian response. The same pattern in a woman of 36 with sudden cycle changes may reflect something quite different and would usually prompt repeat testing and a wider assessment 1. Low or ordinary results during perimenopause are common and do not rule the transition out, because the hormonal picture fluctuates.
Third, the next step. A result that sits outside the standard range is information, not a verdict, and it is worth discussing with a clinician who can combine it with your cycle history, symptoms, medical history and examination. A result that comes with symptoms you find alarming, or bleeding that has changed sharply, is worth discussing with a clinician promptly rather than at the next convenient appointment.
What a result never does on its own is diagnose. Menopause itself is still defined by 12 months without a period, not by a number on a report, and a lab value cannot override that clinical definition.
The markers worth adding are the ones that explain overlapping symptoms and the ones that track the health risks that shift during these years.
| Marker | What it reflects | Why it is often looked at during the transition |
|---|---|---|
| FSH | Pituitary signalling to the ovaries | Rises as ovarian response falls, though it fluctuates between cycles |
| Estradiol | The main ovarian estrogen | Swings widely in perimenopause before settling at a low level afterwards |
| LH | The second pituitary gonadotrophin | Read alongside FSH for a fuller view of the feedback loop |
| AMH | The size of the remaining follicle pool | The steadiest single signal of ovarian reserve |
| TSH and free T4 | Thyroid function | Thyroid symptoms overlap heavily with transition symptoms |
| Ferritin and full blood count | Iron stores and red cells | Bleeding patterns often change before periods stop |
| Lipid panel | Circulating cholesterol and triglycerides | Commonly reviewed as cardiometabolic risk shifts with age |
| HbA1c and fasting insulin | Longer term glucose control and insulin signalling | Body composition and glucose handling often change in these years |
| Vitamin D | Vitamin D status | Relevant to bone health, which is sensitive to estrogen over time |
These are typical lab panels rather than a required list, and ranges vary by lab, age and sex.
Research suggests that the menopause transition is associated with adverse changes in body composition, lipids and vascular measures, which is why an American Heart Association scientific statement frames these years as a window for early prevention 7. That is the practical argument for testing more than hormones. The hormonal picture tells you where you are in the transition. The cardiometabolic and bone-related markers tell you what the transition is doing to the rest of the system, and those are the numbers that respond to attention over the following decades.
The transition typically runs for several years rather than months, and symptoms frequently continue past the final period rather than stopping with it.
The pattern most people describe has three phases. Early on, cycles change in length and bleeding character while symptoms come and go. In the late transition, gaps between periods lengthen and symptoms often peak. After the final period, hormone levels stabilise at a lower level, and many symptoms ease gradually while some, particularly genitourinary ones, may persist or appear later.
Because the end point is only recognised retrospectively, the question of duration is usually answered backwards. Someone who realises they are 11 months into a gap is already nearly there. Someone with irregular cycles at 46 may still be several years away. The detailed version of this question is covered in the guide to how long does menopause last.
Timing matters because the years of ovarian hormone exposure, and the age at which that exposure ends, track with long-term health outcomes. Research suggests that early menopause is associated with higher long-term risks to cardiovascular and bone health, and reviews of care after an early menopause focus on monitoring and managing those risks over the following decades 8.
For menopause at the usual age, the point is less about risk categories and more about the shift in trajectory. The transition is a period when lipids, body composition, blood pressure and vascular measures tend to move in an unfavourable direction, and an American Heart Association scientific statement makes the case for acting on those changes early rather than waiting 7. The implication is practical. The years around the transition are a good time to know your numbers, because the interventions that matter most, such as resistance training, protein intake, sleep and cardiometabolic monitoring, work best when they start before problems consolidate.
Bone is the other long-running theme. Bone density is sensitive to estrogen over time, which is why clinicians pay closer attention to bone health after menopause, and sooner in women whose transition came early 8. Where a management step is appropriate, the decision belongs to a licensed provider who can weigh the full clinical picture.
None of this makes menopause a disease. It makes the transition a useful checkpoint, a moment where measuring is more valuable than guessing.
Talk to a clinician whenever the pattern falls outside what is expected for your age, and promptly if bleeding changes sharply. Specific situations worth raising include the following.
It is equally worth saying what does not need urgent attention. Cycle length drifting by a few days, an occasional skipped period in your late forties, or a single hormone value that sits slightly outside a reference range are common findings during the transition and are usually best handled by repeat testing in context rather than by alarm.
Never ignore an abnormal result, and never conclude a diagnosis from one. Bring the number, the dates and the symptom history to a clinician and let the pattern be interpreted as a whole.
Repeat testing turns noisy individual values into a readable direction of travel, which is the only thing hormone testing does well during the transition. One result tells you where a marker sat on one morning. Three results across a year, taken with the cycle day recorded, tell you whether ovarian output is holding steady or falling, and whether symptoms line up with measurable change.
A few practical points make the data usable. Note the cycle day, or the number of days since the last period if cycles have become unpredictable. Keep to the same lab where possible, since assays and reference ranges differ. Record symptoms alongside the numbers, because the symptom timeline often moves before the lab timeline does. Review hormones alongside thyroid, iron, lipid and glucose markers rather than in isolation, since several of those can produce symptoms that are easily attributed to the transition.
FitScript is built around this kind of longitudinal view, with 150+ biomarkers tested per year and interpretation by Atlas, FitScript's AI health advisor, which reads results as a trend across the full panel rather than as isolated values, and any treatment decisions belong to a licensed provider who has reviewed the member.
This article is educational and is not medical advice. Discuss your own results, your symptoms and any next step with a clinician or licensed provider who knows your history.
The figure usually quoted is around 51, with most women reaching menopause somewhere between 45 and 55. That number is a midpoint for a group rather than a prediction for one person. Reaching menopause at 47 or at 54 is still within the ordinary range.
The transition leading up to menopause most often begins in the forties, and sometimes in the late thirties, with cycles becoming shorter, longer or less predictable. Menopause itself is the end point of that process, the day 12 consecutive months have passed without a period. So the start of the change and the official date are often several years apart.
Menopause before 45 is described as early, and loss of ovarian function before 40 is described as premature ovarian insufficiency. It happens to a meaningful number of women, but it is outside the expected window and is worth raising with a clinician rather than assuming it is nothing. A clinician decides what assessment, if any, is appropriate.
Not precisely. Markers such as AMH give a sense of remaining ovarian reserve and can narrow the likely window, but they do not set a date for an individual. Testing is most informative when it is repeated over time and read alongside your cycle history and symptoms.
No. FSH tends to rise as the ovaries become less responsive, but during the transition it can move a lot from one cycle to the next, so one raised value settles nothing. Menopause is still defined clinically by 12 consecutive months without a period. A clinician interprets any result in the context of your age, cycle pattern and symptoms.
Family timing is one of the better clues available, and mothers, sisters and daughters often fall within a similar window. It is a signal rather than a rule, and surgical history and other medical factors can shift things considerably. Treat it as useful background when you discuss your own timeline with a clinician.
Removal of both ovaries ends ovarian hormone production immediately rather than gradually, which is referred to as induced menopause. Removal of the uterus alone stops periods but leaves ovaries that are still producing hormones, so the hormonal change happens later without a bleeding calendar to mark it. Anyone planning that kind of surgery should discuss the hormonal consequences with the clinician arranging it.
Speak to a clinician if periods stop or become markedly irregular before 45, if bleeding becomes much heavier or more frequent than your normal pattern, or if symptoms are affecting sleep, mood or daily function. Any bleeding that returns after 12 months without a period should be discussed with a clinician promptly. Bring your dates, your symptom notes and any previous results to the appointment.